Current and emerging detoxification therapies for critical care

Materials

Volumn 3, Issue 4, 2010, Pages 2483-2505

  Howell, Brett A ^a   Chauhan, Anuj ^a  

^a University of Florida   (United States)

Author keywords

Antibody fragments; Detoxification; Emulsions; Fab; Liposomes; Overdose

Indexed keywords

ANTIBODY FRAGMENT; DETOXIFICATION THERAPIES; ENVIRONMENTAL CHEMICALS; FAB; KEY DESIGN PARAMETERS; OVERDOSE; PRESCRIPTION DRUGS; TRICYCLIC ANTIDEPRESSANTS;

ANTIBODIES; BINDING ENERGY; BIOCOMPATIBILITY; COLLOIDS; EMULSIONS; LIPOSOMES; TOXICITY;

DETOXIFICATION;

EID: 79960935367     PISSN: None     EISSN: 19961944     Source Type: Journal    
DOI: 10.3390/ma3042483     Document Type: Review

References (87)

1. Wysowski, D.K. Surveillance of prescription drug-related mortality using death certificate data. Drug Safety 2007, 30, 533-540.
2. Henry, J.A.; Alexander, C.A.; Sener, E.K. Relative mortality from overdose of antidepressants. Brit. Med. J. 1995, 310, 221-224.
3. Kerr, G.W.; McGuffie, A.C.; Wilkie, S. Tricyclic antidepressant overdose: A review. Emerg. Med. J. 2001, 18, 236-241.
4. Kiyan, S.; Aksay, E.; Yanturali, S.; Atilla, R.; Ersel, M. Acute myocardial infarction associated with amitriptyline overdose. Basic Clin. Pharmacol. Toxicol. 2006, 98, 462-466.
5. Liebelt, E.L.; Francis, P.D. Cyclic Antidepressants. In Goldfrank's Toxicologic Emergencies, 7th ed.; Goldfrank, L.R., Flomenbaum, N.E., Lewin, N.A., Howland, M.A., Hoffman, R.S., Nelson, L.S., Eds.; McGraw-Hill: New York, NY, USA; pp. 847-864.
6. Morgan, O.; Griffiths, C.; Baker, A.; Majeed, A. Fatal toxicity of antidepressants in England and Wales, 1993-2002. Health Stat. Quart. 2004, 23, 18-24.
7. Prahlow, J.A.; Landrum, J.E. Amitriptyline abuse and misuse. Am. J. Forensic Med. Pathol. 2005, 26, 86-88.
8. Nau, C.; Seaver, M.; Wang, S.; Wang, G.K. Block of human heart hH1 sodium channels by amitriptyline. J. Pharmacol. Exp. Ther. 2000, 292, 1015-1023.
9. Zima, A.V.; Qin, J.; Fill, M.; Blatter, L.A. Tricyclic antidepressant amitriptyline alters sarcoplasmic reticulum calcium handling in ventricular myocytes. Am. J. Physiol-Heart 2008, 295, H2008-H2016.
10. Heard, K.; Cain, B.S.; Dart, R.C.; Cairns, C.B. Tricyclic antidepressants directly depress human myocardial mechanical function independent of effects on the conduction system. Acad. Emerg. Med. 2001, 8, 1122-1127.
11. Unverir, P.; Atilla, R.; Karcioglu, O.; Topacoglu, H.; Demiral, Y.; Tuncok, Y. A retrospective analysis of antidepressant poisonings in the emergency department: 11-year experience. Hum. Exp. Toxicol. 2006, 25, 605-612.
12. Ludot, H.; Tharin, J.Y.; Belooudah, M.; Mazoit, J.X.; Malinovsky, J.M. Successful resuscitation after ropivacaine and lidocaine-induced ventricular arrhythmia following posterior lumbar plexus block in a child. Anesth. Analg. 2008 106, 1572-1574.
13. Warren, J.; Brian, T.; Georgescu, A.; Shah, S. Intravenous lipid infusion in the successful resuscitation of local anesthetic-induced cardiovascular collapse after supraclavicular brachial plexus block. Anesth. Analg. 2008, 106, 1578-1580.
14. Litz, R.J.; Roessel, T.; Heller, A.R.; Stehr, S.N. Reversal of central nervous system and cardiac toxicity after local anesthetic intoxication by lipid emulsion injection. Anesth. Analg. 2008, 106, 1575-1577.
15. Whiteside, J. Reversal of local anaesthetic induced CNS toxicity with lipid emulsion. Anaesthesia 2008, 63, 202-213.
16. Kaufman, B.; Wahlander, S. Local Anesthetics. In Goldfrank's Toxicologic Emergencies, 7th ed.; Goldfrank, L.R., Flomenbaum, N.E., Lewin, N.A., Howland, M.A., Hoffman, R.S., Nelson, L.S., Eds.; McGraw-Hill: New York, NY, USA, 2002; pp. 824-834.
17. Nau, C.; Wang, S.; Strichartz, G.R.; Wang, G.K. Block of human heart hh1 sodium channels by the enantiomers of bupivacaine. Anesthesiology 2000, 93, 1022-1033.
18. Hack, J.B.; Lewin, N.A. Cardioactive Steroids. In Goldfrank's Toxicologic Emergencies, 8th ed.; Flomenbaum, N.E., Goldfrank, L.R., Hoffman, R.S., Howland, M.A., Lewin, N.A., Nelson, L., Eds.; McGraw-Hill: New York, USA, 2006; pp. 971-988.
19. Hull, M.J.; Juhascik, M.; Mazur, F.; Flomenbaum, M.A.; Behonick, G.S. Fatalities associated with fentanyl and co-administered cocaine or opiates. J. Forensic Sci. 2007, 52, 1383-1388.
20. Martin, T.L.; Woodall, K.L.; McLellan, B.A. Fentanyl-Related Deaths in Ontario, Canada: Toxicological findings and circumstances of death in 112 cases (2002-2004). J. Anal. Toxicol. 2006, 30, 603-610.
21. Bernstein, K.T.; Bucciarelli, A.; Piper, T.M.; Gross, C.; Tardiff, K.; Galea, S. Cocaine- and opiate-related fatal overdose in New York City, 1990-2000. BMC Public Health 2007, 7, 31-42.
22. Nelson, L.S. Opioids. In Goldfrank's Toxicologic Emergencies, 8th ed.; Flomenbaum, N.E., Goldfrank, L.R., Hoffman, R.S., Howland, M.A., Lewin, N.A., Nelson, L., Eds.; McGraw-Hill: New York, NY, USA, 2006; pp. 590-619.
23. Yip, L. Ethanol. In Goldfrank's Toxicologic Emergencies, 7th ed.; Goldfrank, L.R., Flomenbaum, N.E., Lewin, N.A., Howland, M.A., Hoffman, R.S., Nelson, L.S., Eds.; McGraw-Hill: New York, NY, USA, 2002; pp. 952-970.
24. Andrews, P. Cocaethylene toxicity. J. Addict. Dis. 1997, 16, 75-84.
25. Hollander, J.E.; Hoffman, R.S. In Goldfrank's Toxicologic Emergencies, 7th ed.; Goldfrank, L.R., Flomenbaum, N.E., Lewin, N.A., Howland, M.A., Hoffman, R.S., Nelson, L.S., Eds.; McGraw-Hill: New York, NY, USA, 2002; pp. 1004-1019.
26. Buckley, N.A.; Roberts, D.; Eddleston, M. Overcoming apathy in research on organophosphate poisoning. Br. Med. J. 2004, 329, 1231-1233.
27. Lian, T.; Ho, R.J.Y. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 2001, 90, 667-680.
28. Szoka, F.; Papahadjopoulos, D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann. Rev. Biophys. Bioeng. 1980, 9, 467-508.
29. MacDonald, R.C.; MacDonald, R.I.; Menco, B.P.; Takeshita, K.; Subbarao, N.K.; Hu, L.R. Smallvolume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim. Biophys. Acta 1991, 1061, 297-303.
30. Kapoor, Y.; Howell, B.A.; Chauhan, A. Liposome assay for evaluating ocular toxicity of surfactants. Investig. Ophthalmol. Vis. Sci. 2009, 50, 2727-2735.
31. Dhanikula, A.B.; Lafleur, M.; Leroux, J. Characterization and in vitro evaluation of spherulites as sequestering vesicles with potential application in drug detoxification. Biochim. Biophys. Acta 2006, 1758, 1787-1796.
32. Letchford, K.; Burt, H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 2007, 65, 259-269.
33. Varshney, M.; Morey, T.E.; Shah, D.O.; Flint, J.A.; Moudgil, B.M.; Seubert, C.N.; Dennis, D.M. Pluronic microemulsions as nanoreservoirs for extraction of bupivacaine from normal saline. J. Am. Chem. Soc. 2004, 126, 5108-5112.
34. Fox, S.I. Human Physiology, 9th ed.; McGraw-Hill: New York, NY, USA, 2006; pp. 383-494.
35. Ishida, T.; Harashima, H.; Kiwada, H. Liposome Clearance. Bioscience Rep. 2002, 22, 197-224.
36. Dams, E.T.M.; Laverman, P.; Oyen, W.J.G.; Storm, G.; Scherphof, G.L.; Van Der Meer, J.W.M.; Corstens, F.H.M.; Boerman, O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292, 1071-1079.
37. Gregoriadis, G.; Senior, J. The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett. 1980, 119, 43-46.
38. Semple, S.C.; Chonn, A.; Cullis, P.R. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behavior in vivo. Adv. Drug Deliver. Rev. 1998, 32, 3-17.
39. Awasthi, V.D.; Garcia, D.; Goins, B.A.; Phillips, W.T. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm. 2003, 253, 121-132.
40. Woodle, M.C. Controlling liposome blood clearance by surface-grafted polymers. Adv. Drug Deliver. Rev. 1998, 32, 139-152.
41. Awasthi, V.D.; Garcia, D.; Klipper, R.; Goins, B.A.; Phillips, W.T. Neutral and anionic liposomeencapsulated hemoglobin: Effect of postinserted poly(ethylene glycol)-distearoylphosphatidylethanolamine on distribution and circulation kinetics. J. Pharmacol. Exp. Ther. 2004, 309, 241-248.
42. Hoarau, D.; Delmas, P.; David, S.; Roux, E.; Leroux, J.C. Novel long-circulating lipid nanocapsules. Pharm. Res. 2004, 21, 1783-1789.
43. Lee, C.M.; Choi, Y.; Huh, E.J.; Lee, K.Y.; Song, H.C.; Sun, M.J.; Jeong, H.J.; Cho, C.S.; Bom, H.S. Polyethylene glycol (PEG) modified 99mTcHMPAO Liposome for improving blood circulation and biodistribution: the Effect of the extent of PEGylation. Cancer Biother. Radio. 2005, 20, 620-628.
44. Howell, B.A.; Chauhan, A. Binding of imipramine, dosulepin, and opipramol to liposomes for overdose treatment. J. Pharm. Sci. 2009, 98, 3718-3729.
45. Lasic, D.D. Novel applications of liposomes. Trends Biotechnol. 1998, 16, 307-321.
46. Dhanikula, A.B.; Lamontagne, D.; Leroux, J.C. Rescue of amitriptyline-intoxicated hearts with nanosized vesicles. Cardiovasc. Res. 2007, 74, 480-486.
47. Dhanikula, A.B.; Khalid, N.M.; Lee, S.D.; Yeung, R.; Risovic, V.; Wasan, K.M.; Leroux, J. Long circulating lipid nanocapsules for drug detoxification. Biomaterials 2007, 28, 1248-1257.
48. Fallon, M.S.; Chauhan, A. Sequestration of amitriptyline by liposomes. J. Colloid Interf. Sci. 2006, 300, 7-19.
49. Howell, B.; Chauhan, A. Uptake of amitriptyline and nortriptyline with liposomes, proteins, and serum: Implications for drug detoxification. J. Colloid Interf. Sci. 2008, 319, 81-93.
50. Howell, B.; Chauhan, A. Amitriptyline overdose treatment by pegylated anionic liposomes. J. Colloid Interf. Sci. 2008, 324, 61-70.
51. Howell, B.A.; Chauhan A. Bupivacaine binding to pegylated liposomes. Anesth. Analg. 2009, 109, 678-682.
52. Howell, B.A.; Chauhan, A. Interaction of cationic drugs with liposomes. Langmuir 2006, 25, 12056-12065.
53. Howell, B.A.; Chauhan, A. A physiologically based pharmacokinetic (pbpk) model for predicting the efficacy of drug overdose treatment with liposomes in man. J. Pharm. Sci. 2010, doi: 10.1002/jps.22115.
54. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005, 94, 1259-1276.
55. Petrikovics, I.; Budai, M.; Baskin, S.I.; Rockwood, G.A.; Childress, J.; Budai, L.; Grof, P.; Klebovich, I.; Szilasi, M. Characterization of liposomal vesicles encapsulating rhodanese for cyanide antagonism. Drug Deliv. 2009, 16, 312-319.
56. Budai, M.; Chapela, P.; Grof, P.; Zimmer, A.; Wales, M.E.; Wild, J.R.; Klebovich, I.; Petrikovics, I.; Szilasi, M. Physicochemical characterization of stealth liposomes encapsulating an organophosphate hydrolyzing enzyme. J. Liposome Res. 2009, 19, 163-168.
57. Petrikovics, I.; Papahadjopoulos, D.; Hong, K.; Cheng, T.C.; Baskin, S.I.; Jiang, J.; Jaszberenyi, J.C.; Logue, B.A.; Szilasi, M.; McGuinn, W.D.; Way, J.L. Comparing therapeutic and prophylactic protection against the lethal effect of paraoxon. Toxicol. Sci. 2004, 77, 258-262.
58. Petrikovics, I.; Cheng, T.C.; Papahadjopoulos, D.; Hong, K.; Yin, R.; DeFrank, J.J.; Jaing, J.; Song, Z.H.; McGuinn, W.D.; Sylvester, D.; Pei, L.; Madec, J.; Tamulinas, C.; Jaszberenyi, J.C.; Barcza, T.; Way, J.L. Long circulating liposomes encapsulating organophosphorus acid anhydrolase in diisopropylfluorophosphate antagonism. Toxicol. Sci. 2000, 57, 16-21.
59. Petrikovics, I.; McGuinn, W.D.; Sylvester, D.; Yuzapavik, P.; Jiang, J.; Way, J.L.; Papahadjopoulos, D.; Hong, K.; Yin, R.; Cheng, T.C.; DeFrank, J.J. Health statistics quarterly studies on sterically stabilized liposomes (SL) as enzyme carriers in organophosphorus (OP) antagonism. Drug Deliv. 2000, 7, 83-89.
60. Petrikovics, I.; Hong, K.; Omburo, G.; Hu, Q.Z.; Pei, L.; McGuinn, W.D.; Sylvester, D.; Tamulinas, C.; Papahadjopoulos, D.; Jaszberenyi, J.C.; Way, J.L. Antagonism of paraoxon intoxication by recombinant phosphotriesterase encapsulated within sterically stabilized liposomes. Toxicol. Appl. Pharm. 1999, 156, 56-63.
61. Morey, T.E.; Varshney, M.; Flint, J.A.; Rajasekaran, S.; Shah, D.O.; Dennis, D.M. Treatment of local anesthetic-induced cardiotoxicity using drug scavenging nanoparticles. Nano Lett. 2004, 4, 757-759.
62. James-Smith, M.A.; Shekhawat, D.; Moudgil, B.M.; Shah, D.O. Determination of drug and fatty acid binding capacity to pluronic F127 in microemulsions. Langmuir 2007, 23, 1640-1644.
63. Underhill, R.S.; Jovanovic, A.V.; Carino, S.R.; Varshney, M.; Shah, D.O.; Dennis, D.M.; Morey, T.E.; Duran, R.S. Oil-Filled silica nanocapsules for lipophilic drug uptake: Implications for drug detoxification therapy. Chem. Mater. 2002, 14, 4919-4925.
64. Chakraborty, S.; Somasundaran, P. Sequestration of drugs using poly(acrylic acid) and alkyl modified poly(acrylic acid) nanoparticles. Soft Matter 2006, 2, 850-854.
65. Lee, D.; Baney, R. Detoxification of amitriptyline by oligochitosan derivatives. Biotechnol. Lett. 2004, 26, 713-716.
66. Lee, D.W.; Flint, J.; Morey, T.; Dennis, D.; Partch, R.; Baney, R. Aromatic-Aromatic interaction of amitriptyline: Implication of overdosed drug detoxification. J. Pharm. Sci. 2005, 94, 373-381.
67. Curd, J.; Smith, T.W.; Jaton, J.C.; Haber, E. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proc. Natl. Acad. Sci. USA 1971, 68, 2401.
68. Butler, V.P., Jr.; Schmidt, D.H.; Smith, T.W.; Haber, E.; Raynor, B.D.; Demartini, P. Effects of sheep digoxin specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs. J. Clin. Invest. 1977, 59, 345-359.
69. Lloyd, B.L.; Smith, T.W. Contrasting rates of reversal of digoxin toxicity by digoxin-specific IgG and Fab fragments. Circulation 1978, 58, 280-283.
70. Lapostolle, F.; Borron, S.W.; Verdier, C.; Taboulet, P.; Guerrier, G.; Adnet, F.; Clemessy, J.L.; Bismuth, C.; Baud, F.J. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit. Care Med. 2008, 36, 3014-3018.
71. Lapostolle, F.; Borron, S.W.; Verdier, C.; Arnaud, F.; Couvreur, J.; Megarbane, B.; Baud, F.; Adnet, F. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008, 34, 1448-1453.
72. Pentel, P.R.; Scarlett, W.; Ross, C.A.; Landon, J.; Sidki, A.; Keyler, D.E. Reduction of desipramine cardiotoxicity and prolongation of survival in rats with the use of polyclonal drugspecific antibody Fab fragments. Ann. Emerg. Med. 1995, 26, 334-341.
73. Shelver, W.L.; Keyler, D.E.; Lin, G.; Murtaugh, M.P.; Flickinger, M.C.; Ross, C.A.; Pentel, P.R. Effects of recombinant drug-specific single chain antibody Fv fragment on [3H]-desipramine distribution in rats. Biochem. Pharmacol. 1996, 51, 531-537.
74. Ragusi, C.; Boschi, G.; Risede, P.; Rips, R.; Harrison, K.; Scherrmann, J.M. Influence of various combinations of specific antibody dose and affinity on tissue imipramine redistribution. Brit. J. Pharmacol. 1998, 125, 35-40.
75. Ragusi, C.; Scherrmann, J.M.; Harrison, K.; Smith, D.S.; Rips, R.; Boschi, G. Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. J. Neurochem. 1998, 70, 2099-2105.
76. Heard, K.; Dart, R.C.; Bogdan, G.; O'Malley, G.F.; Burkhart, K.K.; Donovan, J.W.; Ward, S.B. A preliminary study of tricyclic antidepressant (TCA) ovine FAB for TCA toxicity. Clin. Toxciol. 2006, 44, 275-281.
77. Dart, R.; Seifert, S.; Carroll, L.; Clark, R.; Hall, E.; Boyer-Hassen, L.; Curry, S.; Kitchens, C.; Garcia, R. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. Ann. Emerg. Med. 1997, 30, 33-39.
78. Dart, R.C.; Seifert, S.A.; Boyer, L.V.; Clark, R.F.; Hall, E.; McKinney, P.; McNally, J.; Kitchens, C.S.; Curry, S.C.; Bogdan, G.M.; Ward, S.B.; Porter, R.S. A randomized multicenter trial of crotalinae polyvalent immune Fab (Ovine) antivenom for the treatment for crotaline snakebite in the united states. Arch. Intern. Med. 2001, 161, 2030-2036.
79. Weinberg, G.L.; VadeBoncouer, T; Ramaraju, G.A.; Garcia-Amaro, M.F.; Cwik, M.J. Pretreatment or resuscitation with a lipid infusion shifts the dose response to bupivacaine-induced asystole in rats. Anesthesiology 1998, 88, 1071-1075.
80. Wat, C.Y.; Yuen, M.K.; Li, R.W.S.; Leung, G.P.H.; NG, K.F.J. Lipid Emulsion Infusion vs. Standard Cardiac Resuscitation in Management of Ropivacaine Cardiac Toxicity in Pigs. Presented at the Australian and New Zealand College of Anaesthetists Annual Scientific Meeting, Cairns, Queensland, Australia, May 2009.
81. Zausig, Y.A; Zink, W.; Keil, M.; Sinner, B.; Barwing, J.; Wiese, C.H.R.; Graf, B.M. Lipid emulsion improves recovery from bupivacaine-induced cardiac arrest, but not from ropivacaineor mepivacaine-induced cardiac arrest. Anesth. Analg. 2009, 109, 1323-1326.
82. Weinberg, G.; Ripper, R.; Feinstein, D.L.; Hoffman, W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Region. Anesth. Pain M. 2003, 28, 198-202.
83. Litz, R.J.; Popp, M.; Stehr, S.N.; Koch, T. Successful resuscitation of a patient with ropivacaineinduced asystole after axillary plexus block using lipid emulsion. Anaesthesia 2006, 61, 800-801.
84. Rosenblatt, M.A.; Abel, M.; Fischer, G.W.; Itzkovich, C.J.; Eisenkraft, J.B. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006, 105, 217-218.
85. Finn, S.D.H.; Uncles, D.R.; Willers, J.; Sable, N. Early treatment of a quetiapine and sertraline overdose with Intralipid®. Anaesthesia 2009, 64, 191-194.
86. Cave, G.; Harvey, M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: A Systematic review. Acad. Emerg. Med. 2009, 16, 815-824.
87. Clark, R.F. Insectisides: Organic Phosphorous Compounds and Carbamates. In Goldfrank's Toxicologic Emergencies, 8th ed.; Flomenbaum, N.E., Goldfrank, L.R., Hoffman, R.S., Howland, M.A., Lewin, N.A., Nelson, L., Eds.; McGraw-Hill: New York, NY, USA, 2006; pp. 1497-1522.